Skip to content
My WebMD Sign In, Sign Up

Alzheimer's Disease Health Center

Font Size

Drug May Help Diagnose Alzheimer's Earlier

Florbetaben May Aid in Diagnosis of People With Memory Loss

Pros, Cons of Testing continued...

Additionally, a diagnosis can help families in planning and in creating plans to help protect the patient, Doody says.

Another question is whether doctors can read scan results accurately and consistently. Eli Lilly has established a program to train doctors to interpret the results for its drug, Amyvid, and the manufacturers of the other agents, if approved, will presumably do the same.

There are potential pluses, too.

If the tests can help to identify people with Alzheimer's earlier, that will likely advance research, experts say. Some believe that the reason experimental drugs have failed to work up to now is because they have been tested in people whose Alzheimer's disease was too advanced.

Florbetaben Details

Florbetaben and other new drugs like it have not been compared in a head-to-head study, so no one knows which works best.

But one advantage of florbetaben may be that it appears to last relatively long before it loses its radioactivity, Sabbagh says. That means it can be shipped and used at centers worldwide, while others can only be used where they are made.

Also, the researchers took the extra step of making sure florbetaben detects plaques in the areas of the brain it is supposed to -- the gray matter, he says.

The most common side effects were discomfort and bruising in the area where the drug is injected, headache, and flushing. But symptoms were short-lived, Sabbagh says.

The study was funded by maker Bayer Healthcare Berlin, which plans to submit the results with an application for FDA approval.

No cost has been established for florbetaben. Amyvid is estimated to cost $1,600 a dose, and a PET scan can run from $3,000 to $6,000. When Amyvid becomes available in June, Medicare and presumably most other insurers will not immediately cover its expense.

About 5.4 million people are living with Alzheimer's disease, and there are 15.2 million caregivers of people with Alzheimer's and other dementias, according to the Alzheimer's Association.

These findings were presented at a medical conference. They should be considered preliminary, as they have not yet undergone the "peer review" process, in which outside experts scrutinize the data prior to publication in a medical journal.

1|2

Today on WebMD

alzheimer's disease warning signs
ARTICLE
Alzheimers Overview
SLIDESHOW
 
Best Memory Boosting Games
ARTICLE
mri scan of human brain
QUIZ
 
senior man
ARTICLE
daughter and father
ARTICLE
 
Making Diagnosis
Article
Colored mri of brain
ARTICLE
 
Close up of elderly couple holding hands
VIDEO
senior woman with lost expression
ARTICLE
 
Woman comforting ailing mother
ARTICLE
Alzheimers Dementia
ARTICLE